New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Trackinsight Global ETF Survey 2026
WHEA

State Street SPDR MSCI World Health Care UCITS ETF

Passive ETFEquity

The WHEA Exchange Traded Fund (ETF) is provided by State Street Investment Management. It is built to track an index: MSCI World Health Care Capped 35/20 Index. The WHEA ETF provides physical exposure, so by buying it you actually own parts of all the 111 underlying holdings. The dividend policy is capitalization.

Advertisement

Advertisement

API
PerformanceDec 31, 2025 - Oct 30, 2026
-5%0%5%10%15%JANMARMAYJULSEP
Flows
Join for free to unlock
Data as of 09/30/26
Healthcare
97.69%
Consumer Non-Cyclicals
1.31%
Unavailable
0.26%
Other
0.69%
Latest WHEA news

No content available for this fund

FAQ about WHEA

WHEA is a passively managed ETF that invests in the World Health Care segment.
WHEA tracks the MSCI World Health Care Capped 35/20 NTR Index - USD, through a full replication replication method.
WHEA carries a total expense ratio (TER) of 0.3%.
WHEA was introduced to the market on April 29, 2016.
State Street SPDR MSCI World Health Care UCITS ETF, WHEA, is provided by State Street Investment Management. Learn more about State Street Investment Management here.
WHEA oversees €720M in assets as of October 30, 2026.
WHEA follows a capitalizing, meaning it reinvests income within the fund.
As of September 30, 2026, WHEA has significant geographic allocations in USA, Switzerland and United Kingdom.
As of September 30, 2026, WHEA focuses largely on Healthcare and Consumer Non-Cyclicals.
As of September 30, 2026, WHEA holds 111 positions in its portfolio, with 57.74% of assets concentrated in its top 15 holdings.
As of September 30, 2026, WHEA top three holdings include Eli Lilly & Co., Johnson & Johnson and AbbVie, Inc..
The base currency of WHEA is USD.
Data as of 09/30/26
Eli Lilly & Co.
11.13%
Johnson & Johnson
7.66%
AbbVie, Inc.
5.55%
Merck & Co., Inc.
4.31%
UnitedHealth Group, Inc.
4.01%
Roche Holding AG
3.53%
Novartis AG
3.16%
Thermo Fisher Scientific, Inc.
3.02%
AstraZeneca PLC
2.96%
Amgen, Inc.
2.73%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring
Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight